Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

January 07, 2026-- NeuraLight, the leader in developing precision biomarkers for neurology, today announced the completion of PALOMA, a pioneering study comparing eye-movement measures with standard ...

PALOMA study is one of the largest longitudinal studies using eye-movement biomarkers in patients with Parkinson’s diseaseNEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--NeuraLight, the leader in ...

My words, thoughts, and ideas are now submerged deep in a vat of midnight dark molasses and some days I can no longer ...

SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...

FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to ...

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...

Cytora Therapeutics Ltd. (Cytora), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell ...

Abu Dhabi successfully completes its first gene therapy for genetic blood disorders, revolutionizing treatment approaches for ...

A foster mother who took in Armenta and Lemke's other children is speaking out about the steps they took to help prevent the ...

Former radio DJ Kim Johnston is suffering from symptoms like severe speech impairment, jaw instability and is dependent on a ...

AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated in the United States Therapy granted United States Food and Drug Administration (FDA) Fast Track and Orphan Drug designations ...